Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Kaposi's sarcoma in children: An open randomised trial of vincristine, oral etoposide and a combination of vincristine and bleomycin
European Journal of Cancer, Volume 50, No. 8, Year 2014
Notification
URL copied to clipboard!
Description
Introduction Kaposi's sarcoma (KS) is a common childhood cancer in places where HIV is endemic and access to antiretroviral therapy (ART) is delayed. Despite this there are no randomised trials to compare and assess chemotherapeutic regimens. Method An open label, randomised trial comparing intravenous vincristine alone, vincristine and bleomycin and oral etoposide, was carried out in children with Kaposi's sarcoma in the Queen Elizabeth Central Hospital, Blantyre, Malawi. HIV infected children were given ART after 2-3 courses of chemotherapy if they were not already on treatment. Neither HIV nor widespread KS are curable and treatment is aimed at disease reduction and improved quality of life. Tumour reduction was assessed by measuring the size of sentinel KS nodules and quality of life (QoL) by using the Lansky score. Follow up was until death or for one year. Findings 92 children were enrolled of whom 46% were naïve to ART; 10 (11%) were HIV negative. Survival was not influenced by age or gender but was better in the oral etoposide and the vincristine and bleomycin groups. P = 0.0045. The group receiving oral etoposide had a better quality of life. Toxicity was not significant, and any drop in haemoglobin or white cell count could have been causally related to HIV infection rather than cytotoxic therapy. Conclusion Oral etoposide is a safe, effective treatment to contain KS and improve QoL which can be achieved without many visits to the hospital and intravenous injections. © 2014 Elsevier Ltd. All rights reserved.
Authors & Co-Authors
Chagaluka, George
Malawi, Blantyre
Queen Elizabeth Central Hospital Malawi
Stanley, Christopher Chikhosi
Malawi, Zomba
University of Malawi
Banda, Kondwani
Malawi, Blantyre
Queen Elizabeth Central Hospital Malawi
Depani, Sarita J.
United Kingdom, London
The Royal Marsden Hospital
Nijram'Madzi, Jenala
Malawi, Blantyre
Queen Elizabeth Central Hospital Malawi
Katangwe, Thembi
Malawi, Blantyre
Queen Elizabeth Central Hospital Malawi
Malawi, Blantyre
Kamuzu University of Health Sciences
Israëls, Trijn
Netherlands, Amsterdam
Amsterdam Umc - Vrije Universiteit Amsterdam
Bailey, Simon
United Kingdom, Newcastle
Great North Children's Hospital
Mukaka, Mavuto F.J.
Malawi, Blantyre
Malawi-liverpool-wellcome Trust Clinical Research Programme
Molyneux, Elizabeth M.
Malawi, Blantyre
Queen Elizabeth Central Hospital Malawi
Malawi, Blantyre
Kamuzu University of Health Sciences
Statistics
Citations: 28
Authors: 10
Affiliations: 7
Identifiers
Doi:
10.1016/j.ejca.2014.02.019
ISSN:
09598049
e-ISSN:
18790852
Research Areas
Cancer
Disability
Health System And Policy
Infectious Diseases
Maternal And Child Health
Study Locations
Malawi